Today’s rally breaks the stock into new-high territory in a clear move by investors to start buying HIM stock ahead of its next quarterly report on March 3. The move is also being fueled by a positive ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. Not even on Valentine ...

Lifestyle changes should both precede and accompany ED treatments. Healthy lifestyle behaviors can have a positive impact on some of the psychological (ie, stress, anxiety, depression) and ...

Here's a wrap-up of news on medicines and clinical treatments, including a win for the AMA, and updates from the TGA, PBS, and MBS, as well as information on new guidelines, publications and ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers stock in trouble, or is this just a bump in the road for what could still ...

and it is now also offering treatment plans for Prime members via a telehealth service to help treat areas such as erectile dysfunction and hair loss, which are key areas that Hims & Hers focuses ...

The UK should negotiate a new customs union deal with the European Union, Liberal Democrat leader Sir Ed Davey has said. In a speech in London, he argued it was needed to boost Britain's economy ...